Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:diseases:ibd [02.17.2019] – [Inflammatory bowel disease (Crohn's disease and ulcerative colitis)] sallieqhome:diseases:ibd [03.13.2019] – [Research] sallieq
Line 181: Line 181:
  
 ===== Research ===== ===== Research =====
 +
 +Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely.  (({{pubmed>long:25023670}}))
 +
 +In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.   (({{pubmed>long:25947920}}))
  
 Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.  (({{pubmed>long:25557335}}))  Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.  (({{pubmed>long:25557335}})) 
home/diseases/ibd.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.